Vitamin D Repletion for Level of 14 ng/mL
For a serum 25-hydroxyvitamin D level of 14 ng/mL, treat with 50,000 IU of vitamin D2 or D3 once weekly for 8 weeks, followed by maintenance therapy of 1,500-2,000 IU daily. 1
Treatment Algorithm
Initial Repletion Phase (8 weeks)
The Endocrine Society guideline provides the definitive approach for this level of deficiency:
- Standard dosing: 50,000 IU weekly for 8 weeks (total 400,000 IU)
- Alternative: 6,000 IU daily for 8 weeks if weekly dosing is not feasible
- Target: Achieve 25(OH)D level above 30 ng/mL 1
This regimen is specifically validated for adults with vitamin D deficiency. The guideline explicitly notes that children receiving 14,000 IU weekly increased their levels from 14.8 to 38.31 ng/mL over one year, demonstrating efficacy at this baseline level 1.
Maintenance Phase (After Initial 8 Weeks)
Once repletion is achieved:
- 1,500-2,000 IU daily to prevent recurrence 1
- Alternative: 50,000 IU every other week has been shown effective in maintaining levels between 35-50 ng/mL 1
Special Populations Requiring Higher Doses
Obese patients: Require 2-3 times higher dosing (at least 6,000-10,000 IU daily) due to sequestration in adipose tissue 1
Malabsorption syndromes (celiac disease, cystic fibrosis, inflammatory bowel disease): Also require 6,000-10,000 IU daily 1
Medications affecting vitamin D metabolism (anticonvulsants, glucocorticoids): Need at least 6,000-10,000 IU daily 1
Evidence Supporting This Approach
Research confirms the guideline recommendations. A retrospective study of 306 patients found that regimens containing at least 600,000 IU total achieved sufficiency in 64% of cases 2. The 50,000 IU weekly for 8 weeks regimen (400,000 IU total) falls within this effective range.
More recent data from 2023 showed that 100,000 IU weekly for 12 weeks sustained therapeutic levels over three months 3, though this exceeds guideline recommendations and should be reserved for specific clinical scenarios.
Critical Monitoring Points
Verify compliance first: If levels don't increase appropriately after 8 weeks, evaluate for:
- Non-adherence to prescribed regimen
- Celiac disease
- Cystic fibrosis
- Other malabsorption disorders 1
Special monitoring situations:
- Granulomatous diseases (sarcoidosis, tuberculosis): Monitor calcium levels closely as activated macrophages produce 1,25(OH)2D unregulated, risking hypercalcemia when 25(OH)D exceeds 30 ng/mL 1
- Primary hyperparathyroidism: Can treat vitamin D deficiency but monitor serum calcium 1
Practical Considerations
Formulation choice: Both vitamin D2 (ergocalciferol) and D3 (cholecalciferol) are effective for repletion 1. However, adherence data shows cholecalciferol has superior medication possession ratio (87% vs 68%) 4, making it preferable when available.
Dosing frequency: Weekly dosing is as effective as daily dosing for repletion and reduces pill burden 5. At a baseline of 14 ng/mL, research shows 300,000 IU cumulative cholecalciferol achieves therapeutic levels in 90% of patients 4, supporting the 400,000 IU total in the guideline regimen.
Common Pitfalls to Avoid
- Don't use maintenance doses for repletion: Daily doses of 600-1,100 IU only increase levels by 8-9 ng/mL, insufficient for someone starting at 14 ng/mL 4
- Don't skip maintenance therapy: Without ongoing supplementation, deficiency recurs
- Don't assume linear dose-response: The relationship between dose and level increase is not linear, particularly at higher doses 4
- Don't forget body weight: Dose-response is related to dose per kilogram body weight 6